| | |  | | | | Record from Web of Science® | | | | | | |
| Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients |
|
|
| Author(s): Levin NW, Hoenich NA |
| Source: CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION Volume: 10 Issue: 5 Pages: 563-568 Published: SEP 2001 |
| Times Cited: 40 References: 27 |
| Abstract: Control of serum phosphorus levels is a central goal in the management of patients with chronic renal failure. Inadequate control of serum phosphorus leads to elevated levels of the calcium-phosphorus product. This plays a pivotal role in vascular calcification, cardiovascular disease, calciphylaxis, and death. Elevated phosphorus and elevated levels of the calcium-phosphorus product are both significant predictors of cardiovascular mortality, at phosphorus and calcium-phosphorus product levels that were considered safe until recently. A lowering of levels such that phosphorus is maintained between 2.2 and 5.5 mg/dl calcium-phosphorus product is below 55 mg(2)/dl(2), and serum calcium is at 9.2-9.6 mi respectively, might well be the goal of therapeutic management strategies. Curr Opin Nephrol Hypertens 10:563-568. (C) 2001 Lippincott Williams & Wilkins. |
| Document Type: Review |
| Language: English |
| Reprint Address: Levin, NW (reprint author), Renal Res Inst, 207 E 94th St, New York, NY 10128 USA |
Addresses:
1. Renal Res Inst, New York, NY 10128 USA |
| Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA |
| Subject Category: Urology & Nephrology; Peripheral Vascular Disease |
| IDS Number: 467QA |
| ISSN: 1062-4821 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |